| Name | Title | Contact Details |
|---|
Cytovia is dedicated to the development of transformational cancer immunotherapies, addressing several of the most challenging unmet medical needs including the prevention of cancer relapse and metastasis. Cytovia focuses on Natural Killer (NK) cell biology and applies precision medicine tools to develop the right therapy for the right patient at the right stage of the disease. Cytovia has secured access to multiple advanced technologies, including allogeneic cell therapy, multispecific antibodies, and cytokines. Cytovia establishes development partnerships to accelerate time-to-market and commercialization alliances in order to optimize rapid adoption of its novel immunotherapies.
Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis™ technology platform. Using biological components from each patient, Arcelis-based immunotherapies employ the patient`s dendritic cells to activate an immune response specific to the patient`s disease. Argos` most advanced product candidates include AGS-003 for the treatment of metastatic renal cell carcinoma, or mRCC, and AGS-004 for the treatment of HIV. Argos Therapeutics is headquartered in Research Triangle Park, NC. The Company has clinical stage programs in Phase 3 (metastatic renal cell carcinoma), Phase 2b (HIV) and Phase 1a (systemic lupus erythematosus1) development.
TearClear is an emerging ophthalmic pharmaceutical company with the goal of disrupting the way current topical medications are delivered to the ocular surface. Our lead product candidates in glaucoma will pave the way for future indications across multiple programs in development.
PharmaCord is the key connector between manufacturers, patients, physicians and payors. We provide innovative solutions that drive efficient and rapid access to life saving therapies. At PharmaCord, we help biopharma companies by delivering tailored solutions that alleviate product access hurdles and drive commercial success. Programs are configured with a focus on key stakeholders in a product`s success including physicians, patients and payors. Services are accessed through our CAPS (Centralized Access Patient Services) Center. Rapid uptake and continuation of therapy are the results our clients see. While the name of the company is new, our leadership is not. Over the years our team has provided support to millions of patients and driven commercial success for our client`s products. The leadership team of the company have led the launch of over 40 different products and transitioned dozens of programs spanning a 20-year period.
Thermo Fisher Scientific Inc is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. With revenues of $13 billion, we have approximately 39,000 employees and serve customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as in environmental and process control industries. We create value for our key stakeholders through three premier brands, Thermo Scientific, Fisher Scientific and Unity™ Lab Services, which offer a unique combination of innovative technologies, convenient purchasing options and a single solution for laboratory operations management. Our products and services help our customers solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity.